August 1, 2018
GE Healthcare, Lantheus launch 2nd Phase 3 trial of PET imaging agent
GE Healthcare and Lantheus have started a second Phase 3 clinical trial of flurpiridaz 18F, an investigational agent being evaluated for the detection of coronary artery disease. (read more here)